Takeda Pharmaceutical Company Limited

Yusuke Tominari

Yusuke Sasaki

Shinichi Imamura

Akito Shibuya

Zenyu Shiokawa

Terufumi Takagi

Masato Yoshikawa

Masaki Seto

Masato Yoshida

Masanori Okaniwa

Michiyo Mochizuki

Morihisa Saitoh

Tomohiro Seki

Kosuke Hidaka

Yoshihisa Nakada

Yayoi Nakayama

Yasuo Nakagawa

Taisuke Kato

Daisuke Tomita

Tsuneo Oda

Kazuaki Takami

Takaharu Hirayama

Yasuhiro Hirata

Paul D Greenspan

Tony Gibson

Yasufumi Wada

Brian Scott Freeze

Taisuke Tawaraishi

Moriteru Asano

Naoki Iwamura

Naoki Tomita

Shumpei Murata

Atsutoshi Okabe

Koji Ono

Yasushi Hattori

Satoru Matsuda

Takuto Kojima

Masashi Toyofuku

Tomohiro Kaku

Kazuhiro Miwa

Shigemitsu Matsumoto

Atsushi Hasuoka

Mitsuhiro Ito

Shinji Morimoto

Douglas Robert Cary

Takashi Ichikawa

Taisuke Katoh

Yayoi Yoshitomi

Shigeo Kajii

Ken Tsuchida

Ryujiro Hara

The present disclosure provides a compound having a STING agonistic activity, which may be expected to be useful as an agent for the prophylaxis or treatment of STING-related diseases. The present disclosure relates to a compound represented by the formula (I): wherein each symbol is as defined in the description, or a salt thereof.

Methods of making a cyclic dinucleotide

Antibody-drug conjugates comprising a cyclic dinucleotide

Cyclic dinucleotide

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof.

Heterocyclic amide compound

Provided is a heterocyclic amide compound that may have a PRS inhibitory action and is expected to be useful as a prophylactic or therapeutic agent for PRS associated diseases and the like including cancer. A compound represented by the following formula (I): wherein a group represented by is a group represented by the following formula (II) or the following formula (III): and other symbols are as described in the DESCRIPTION, or a salt thereof.

The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Heterocyclic compound

The present invention provides a compound having a lysine specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, Alzheimer's disease, Parkinson's disease or Huntington's disease, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group optionally having substituent(s), or a heterocyclic group optionally having substituent(s);

Cyclopropanamine compound and use thereof

The present invention provides a compound having a lysine-specific demethylase 1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for cancer, and central nervous system diseases, and the like. The present invention relates to a compound represented by the formula wherein A is a hydrocarbon group or heterocyclic group optionally having substituent(s); R is H, a hydrocarbon group or heterocyclic group optionally having substituent(s); A and R are optionally bonded to each other to form a ring optionally having substituent(s); Q, Q, Qand Qare each a hydrogen atom or a substituent; Qand Q, and Qand Q, are each optionally bonded to each other to form a ring optionally having substituent(s); X is H, an acyclic hydrocarbon group or saturated cyclic group optionally having substituent(s); Y, Yand Yare each H, a hydrocarbon group or heterocyclic group optionally having substituent(s); X and Y, and Yand Y, are each optionally bonded to each other to form a ring optionally having substituent(s); and Z, Zand Zare each H or a substituent, or a salt thereof.

Cyclopropaneamine compound

The present invention provides a novel compound having a superior activity as an ERR-&#x3b1; modulator and useful as an agent for the prophylaxis or treatment of ERR-&#x3b1; associated diseases. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

Nitrogen-containing heterocyclic compound

Growing community of inventors

Kanagawa, Japan

Yusuke Tominari